LIVE
BPC-157, Thymosin beta-4 (TB-500), and related peptides studied for soft-tissue repair, wound healing, and recovery from connective-tissue injury.
This category covers peptides studied in preclinical and limited clinical models of tissue repair, wound healing, and connective-tissue regeneration.
BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid fragment of a larger gastric-juice protein. Rodent studies report accelerated healing of tendon, ligament, muscle, and gastrointestinal mucosa, with proposed mechanisms including angiogenesis, NO-pathway modulation, and growth-factor signaling. No large human trials have been completed. TB-500 is the research-peptide market's name for a short synthetic fragment related to thymosin beta-4, a 43-amino-acid actin-binding peptide that promotes cell migration, angiogenesis, and re-epithelialization in wound models. Vendors stock both the short TB-500 sequence and full-length thymosin beta-4 preparations.
Adjacent mechanism-specific research peptides round out the class. ARA-290 (cibinetide) is an 11-amino-acid peptide derived from the B-helix of erythropoietin; it retains EPO's cytoprotective and anti-inflammatory activity without the hematopoietic effect, and was studied by Araim Pharmaceuticals for painful diabetic neuropathy. B7-33 is a single-chain relaxin-2 analog under investigation for fibrotic and cardiovascular indications. GHK (glycyl-histidyl-lysine, free base) is a copper-binding tripeptide naturally present in human plasma; its extracellular-matrix-remodeling effects are studied in wound-healing contexts. The copper-chelated form GHK-Cu is catalogued separately under Skin & Cosmetic, where most of its commercial use sits.
None of the peptides in this category are FDA-approved for a healing indication. Research-vendor products are sold as lyophilized powders intended for in-vitro and animal research.